CUSIP: 29970R105
Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / ADS
-
Total 13F shares
-
133,705
-
Share change
-
-27,632
-
Total reported value
-
$115,861
-
Price per share
-
$0.86
-
Number of holders
-
10
-
Value change
-
-$25,462
-
Number of buys
-
3
-
Number of sells
-
5
Quarterly Holders Quick Answers
What is CUSIP 29970R105?
CUSIP 29970R105 identifies EVAX - EVAXION BIOTECH A S - ADS in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2023
-
Previous quarter:
Q2 2023
Recent filing periods for CUSIP 29970R105:
Institutional Holders of EVAXION BIOTECH A S - ADS (EVAX) as of Q3 2023
As of 30 Sep 2023,
EVAXION BIOTECH A S - ADS (EVAX) was held by
10 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
133,705 shares.
The largest 10 holders included
AE Wealth Management LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, TWO SIGMA SECURITIES, LLC, Moloney Securities Asset Management, LLC, JPMORGAN CHASE & CO, Beacon Capital Management, LLC, UBS Group AG, MORGAN STANLEY, RHUMBLINE ADVISERS, and GROUP ONE TRADING, L.P..
This page lists
10
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.